TWEAK-receptor agonists for use in combination with immunotherapy of a cancer

A method for identifying a TWEAK-receptor agonist, the method comprising the steps:

• a) providing tumor cells presenting an antigen-MHC class I complex and lacking functional IFNγ signaling;
• b) contacting the tumor cells of step a) with at least one candidate agonist of interest;
• c) co-incubating the tumor cells obtained from step b) with CD8 T cells expressing a T cell receptor that recognizes the antigen-MHC class I complex presented by the tumor cells of step a);
• d) determining whether the tumor cells in step c) undergo programmed cell death;
• e) identifying a candidate agonist as a TWEAK-receptor agonist if in step d) the tumor cells are determined to undergo programmed cell death at a greater rate than:
• i) corresponding tumor cells contacted with the candidate agonist and co-incubated with CD8 T cells that do express the T cell receptor that recognizes the antigen-MHC class I complex presented by the tumor cells of step a);
• and/or,
• ii) corresponding tumor cells not contacted with the candidate agonist and co-incubated with CD8 T cells expressing the T cell receptor that recognizes the antigen-MHC class I complex presented by the tumor cells of step a).